Yuhan Corporation (000105.KS)
KRW 101900.0
(-3.04%)
KRW 101900.0
(-3.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 127.43 Billion KRW | -32.19% |
| 2022 | 78.06 Billion KRW | -22.43% |
| 2021 | 123.92 Billion KRW | 0.35% |
| 2020 | 238.88 Billion KRW | 56.19% |
| 2019 | 69.64 Billion KRW | -19.2% |
| 2018 | 109.12 Billion KRW | -26.34% |
| 2017 | 201.73 Billion KRW | -17.61% |
| 2016 | 140.71 Billion KRW | 22.11% |
| 2015 | 116.89 Billion KRW | 26.07% |
| 2014 | 100.9 Billion KRW | 12.86% |
| 2013 | 80.74 Billion KRW | 18.61% |
| 2012 | 124.95 Billion KRW | -3.95% |
| 2011 | 82.73 Billion KRW | -21.25% |
| 2010 | 165.07 Billion KRW | -2.68% |
| 2009 | 162.7 Billion KRW | -1.85% |
| 2008 | 169.36 Billion KRW | 29.2% |
| 2007 | 129.8 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 34.71 Billion KRW | 107.44% |
| 2024 Q1 | 15.53 Billion KRW | 180.14% |
| 2023 Q4 | 5.97 Billion KRW | -95.87% |
| 2023 FY | - KRW | -32.19% |
| 2023 Q1 | 54.23 Billion KRW | 193.84% |
| 2023 Q2 | 152.81 Billion KRW | 181.79% |
| 2023 Q3 | 144.49 Billion KRW | -5.45% |
| 2022 FY | - KRW | -22.43% |
| 2022 Q2 | 57.08 Billion KRW | 40.69% |
| 2022 Q1 | 40.57 Billion KRW | -7.12% |
| 2022 Q4 | 18.45 Billion KRW | -44.69% |
| 2022 Q3 | 33.36 Billion KRW | -41.54% |
| 2021 Q1 | 43.26 Billion KRW | 12.31% |
| 2021 Q2 | 57.47 Billion KRW | 32.83% |
| 2021 FY | - KRW | 0.35% |
| 2021 Q3 | 48.38 Billion KRW | -15.81% |
| 2021 Q4 | 43.68 Billion KRW | -9.72% |
| 2020 Q1 | 40.89 Billion KRW | 73.51% |
| 2020 Q3 | 49.4 Billion KRW | -21.83% |
| 2020 Q4 | 38.52 Billion KRW | -22.02% |
| 2020 FY | - KRW | 56.19% |
| 2020 Q2 | 63.2 Billion KRW | 54.56% |
| 2019 Q4 | 23.56 Billion KRW | -30.64% |
| 2019 Q2 | 26.54 Billion KRW | -31.67% |
| 2019 Q1 | 38.84 Billion KRW | 38.02% |
| 2019 FY | - KRW | -19.2% |
| 2019 Q3 | 33.98 Billion KRW | 28.01% |
| 2018 Q2 | 43.81 Billion KRW | -8.28% |
| 2018 FY | - KRW | -26.34% |
| 2018 Q4 | 28.14 Billion KRW | -12.21% |
| 2018 Q3 | 32.06 Billion KRW | -26.83% |
| 2018 Q1 | 47.77 Billion KRW | 5.13% |
| 2017 Q4 | 45.44 Billion KRW | -11.59% |
| 2017 FY | - KRW | -17.61% |
| 2017 Q1 | 53.05 Billion KRW | -29.09% |
| 2017 Q2 | 56.76 Billion KRW | 6.99% |
| 2017 Q3 | 51.39 Billion KRW | -9.45% |
| 2016 Q1 | 75.55 Billion KRW | 99.66% |
| 2016 Q2 | 56.86 Billion KRW | -24.73% |
| 2016 Q3 | 43.45 Billion KRW | -23.59% |
| 2016 FY | - KRW | 22.11% |
| 2016 Q4 | 74.82 Billion KRW | 72.18% |
| 2015 Q3 | 77.77 Billion KRW | 59.26% |
| 2015 Q4 | 37.84 Billion KRW | -51.34% |
| 2015 FY | - KRW | 26.07% |
| 2015 Q1 | 40.86 Billion KRW | -8.71% |
| 2015 Q2 | 48.83 Billion KRW | 19.49% |
| 2014 Q1 | 36.38 Billion KRW | -15.71% |
| 2014 FY | - KRW | 12.86% |
| 2014 Q4 | 44.76 Billion KRW | 6.91% |
| 2014 Q3 | 41.87 Billion KRW | 5.11% |
| 2014 Q2 | 39.83 Billion KRW | 9.5% |
| 2013 Q3 | 27.45 Billion KRW | -26.59% |
| 2013 Q4 | 43.16 Billion KRW | 57.21% |
| 2013 FY | - KRW | 18.61% |
| 2013 Q1 | 36.28 Billion KRW | 29.42% |
| 2013 Q2 | 37.39 Billion KRW | 3.06% |
| 2012 Q2 | 23.84 Billion KRW | 88.86% |
| 2012 Q1 | 12.62 Billion KRW | 0.0% |
| 2012 Q3 | 34.84 Billion KRW | 46.18% |
| 2012 Q4 | 28.03 Billion KRW | -19.54% |
| 2012 FY | - KRW | -3.95% |
| 2011 Q1 | 21.36 Billion KRW | -31.46% |
| 2011 FY | - KRW | -21.25% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 19.41 Billion KRW | 8.23% |
| 2011 Q2 | 17.94 Billion KRW | -16.01% |
| 2010 Q3 | 20.82 Billion KRW | -33.52% |
| 2010 Q2 | 31.31 Billion KRW | 20.95% |
| 2010 Q1 | 25.89 Billion KRW | -24.36% |
| 2010 Q4 | 31.16 Billion KRW | 49.67% |
| 2010 FY | - KRW | -2.68% |
| 2009 Q3 | 25.16 Billion KRW | -13.37% |
| 2009 Q4 | 34.23 Billion KRW | 36.04% |
| 2009 FY | - KRW | -1.85% |
| 2009 Q1 | 24.26 Billion KRW | -12.69% |
| 2009 Q2 | 29.04 Billion KRW | 19.71% |
| 2008 Q4 | 27.79 Billion KRW | 21.16% |
| 2008 FY | - KRW | 29.2% |
| 2008 Q1 | 39.22 Billion KRW | 95.68% |
| 2008 Q2 | 42.36 Billion KRW | 7.99% |
| 2008 Q3 | 22.93 Billion KRW | -45.85% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q1 | 30.49 Billion KRW | 0.0% |
| 2007 Q2 | 38.75 Billion KRW | 27.07% |
| 2007 Q3 | 33.32 Billion KRW | -14.0% |
| 2007 Q4 | 20.04 Billion KRW | -39.85% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -2522.975% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 9.855% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 299.002% |
| HANDOK Inc. | 35.06 Billion KRW | -263.402% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 12393.653% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -239.63% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 687.586% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 60.588% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -2453.601% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -742.908% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -3625.048% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -2715.326% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -259.104% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -2522.975% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 789.878% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -1844.068% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 358.527% |
| JW Holdings Corporation | 187.88 Billion KRW | 32.175% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 348.754% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 55.07% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -42.829% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 443.792% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -864.7% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -977.396% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -583.109% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -2522.975% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | -131.81% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 22.727% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -42.829% |
| Yuhan Corporation | 127.43 Billion KRW | 0.0% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -280.671% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -1565.827% |
| Suheung Co., Ltd. | 77.02 Billion KRW | -65.436% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -42.829% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -247.85% |
| Korea United Pharm Inc. | 70.78 Billion KRW | -80.04% |
| CKD Bio Corp. | -1.63 Billion KRW | 7915.846% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | -155.926% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -291.361% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -246.188% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 443.792% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | -104.599% |
| Boryung Corporation | 114.28 Billion KRW | -11.501% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 516.88% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -742.908% |
| JW Lifescience Corporation | 50.82 Billion KRW | -150.708% |